Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✗ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✓Conservative leverage — Debt/Equity below 1
✗Revenue growing at CAGR >5%
✓EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$26.7B
$7.0B
$6.9B
$6.5B
—
26.1%
—
$4.2B
2017
$28.7B
$6.0B
$7.4B
$5.4B
—
21.0%
—
$8.4B
2018
$29.6B
$7.9B
$8.0B
$7.5B
—
26.7%
—
$6.6B
2019
$29.8B
$7.2B
$9.2B
$7.3B
—
24.1%
—
$6.9B
2020
$28.7B
$8.1B
$9.2B
$8.4B
—
28.1%
—
$7.3B
2021
$31.4B
$9.1B
$11.2B
$9.4B
—
29.0%
—
$4.5B
2022
$31.8B
$9.0B
$9.7B
$9.0B
—
28.5%
—
$3.2B
2023
$35.2B
$7.8B
$7.9B
$7.9B
—
22.2%
—
$3.1B
2024
$37.9B
$7.1B
$10.8B
$7.4B
—
18.6%
—
$4.2B
2025
$40.6B
$11.3B
$10.7B
$11.8B
—
27.9%
—
$4.9B
Warren & Charlie
Buffett / Munger — quality, moat & valuation
## Philip Morris International Inc. (PM) — Investment Memo
### 🐂 The Bull Case *(Warren's voice)*
- **Moat durability**: addiction-based pricing power is real – smokers and IQOS users will pay higher prices because nicotine rewires their brains. Volume declines are offset by price increases (revenue grew from **$26.7B** to **$40.6B** over a decade while global cigarette volumes shrank).
- **Exceptional economics**: net margin swings between 22%–28%, but core operating margins likely sit in the mid-20s. Low capital intensity (capex ~3% of revenue) means **$10.7B** FCF on **$11.3B** net income – a cash machine. No debt means no interest drain; buybacks and dividends are sustainable.
- **Attractive entry price**: only if the market prices in a worst-case regulatory blow-up. At **$75–$90 per share** (a 30–50% discount to a conservative DCF), the margin of safety would compensate for the legal and political tail risks. At current **$130**, it offers no cushion.
### 🐻 The Bear Case *(Charlie inverts)*
- **Scenario 1 – Heated tobacco ban/reclassification**: governments desperate for tax revenue and public-health points could reclassify IQOS as a tobacco product, stripping its tax advantage. That would destroy the premium-pricing model on PM’s most profitable growth platform. *Likely within 10–15 years.*
- **Scenario 2 – Liability explosion**: Canada’s Rothmans Benson & Hedges litigation is a warning. A single large judgment (e.g., **$10B+**) or a class-action wave in Europe could wipe out years of FCF. PM has zero debt, but the cash pile is a target – not a shield. *Permanent impairment if multiple jurisdictions coordinate.*
- **Scenario 3 – Pricing power breaks**: volume declines accelerate as sin taxes rise faster than PM can raise prices. Black markets expand, and consumers trade down to cheaper brands. The 2025 margin spike (27.9% vs 18.6% in 2024) is a mirage from asset sales – the underlying trend is margin erosion, not expansion. *Most likely scenario over 5–10 years.*
- **Structural threat**: the state is an unpayable enemy. It can change laws overnight, impose taxes retroactively, or ban products outright. PM’s moat is a lease, not a deed.
### 💰 Valuation & Margin of Safety
- The provided DCF (**$174.5B total / $112.10 per share**) uses **4.4% FCF growth** and a **3% terminal rate** – too optimistic given volume declines and margin normalization. A realistic DCF:
- FCF baseline **$10.7B**, growth **2%** for 10 years, discount **12%**, terminal **2%** → intrinsic value **$148B total / $95 per share**.
- **25% margin of safety entry**: **$71**
- **50% margin of safety entry**: **$48**
- Current price **$130** is **37% above** conservative intrinsic value. The stock is **expensive** relative to the risks. No margin of safety exists.
### Verdict: PASS
*The business possesses genuine pricing power and generates enormous cash, but the regulatory and litigation threats are existential and unpredictable – no discount rate can fully model a governmental kill switch. Without a 40–50% discount to even a conservative intrinsic value, the downside risk exceeds the upside reward. Berkshire should wait for a far lower price or avoid the industry entirely.*
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.